Table 5.
Common, all-causality adverse events reported in patients with OS ≥24 versus < 24 months in the axitinib titration arm
| Adverse event,a n (%) | OS ≥24 months n = 33 | OS < 24 months n = 20b | ||
|---|---|---|---|---|
| All Grades | Grade ≥ 3 | All Grades | Grade ≥ 3 | |
| Any | 33 (100) | 24 (73) | 19 (95) | 11 (55) |
| Diarrhoea | 27 (82) | 7 (21) | 7 (35) | 0 |
| Hypertension | 24 (73) | 7 (21) | 10 (50) | 3 (15) |
| Fatigue | 18 (55) | 1 (3) | 9 (45) | 2 (10) |
| Nausea | 14 (42) | 1 (3) | 10 (50) | 2 (10) |
| Hand–foot syndrome | 14 (42) | 1 (3) | 4 (20) | 1 (5) |
| Hypothyroidism | 14 (42) | 0 | 4 (20) | 0 |
| Decreased appetite | 12 (36) | 2 (6) | 8 (40) | 2 (10) |
| Weight decrease | 12 (36) | 6 (18) | 4 (20) | 0 |
| Vomiting | 11 (33) | 3 (9) | 8 (40) | 1 (5) |
| Dysphonia | 11 (33) | 0 | 7 (35) | 1 (5) |
| Arthralgia | 10 (30) | 0 | 3 (15) | 1 (5) |
| Stomatitis | 10 (30) | 1 (3) | 0 | 0 |
| Mucosal inflammation | 9 (27) | 1 (3) | 3 (15) | 1 (5) |
| Proteinuria | 9 (27) | 2 (6) | 3 (15) | 0 |
Abbreviation: OS overall survival
aReported by ≥25% in either group
bExcluded 3 patients who were censored < 24 months in OS